PRESS RELEASE |

 

NAXUS® pre-clinical results published in 2 peer reviewed journals. BioActor signs Collaboration Agreement with Ghent University to study the effects of NAXUS on the gut microbiota and gut barrier function.

NAXUS® is a clinically evaluated Arabinoxylan concentrate from wheat. NAXUS has shown profound effects on the human microbiota with potent downstream effects on the improvement of several metabolic processes. Recent pre-clinical results obtained by Ghent University and Universite Catholique de Louvain have been accepted in 2 peer reviewed journals and further strengthen the evidence on health-beneficial effects of NAXUS intake.
BioActor has – moreover – signed a Collaboration Agreement with the Laboratory of Microbial Ecology and Technology (LabMET), Ghent University to further study the effects of NAXUS on the gut microbiota and the downstream effects on gut barrier function.

 

Maastricht, Netherlands, October 1, 2013

NAXUS® is an Arabinoxylan concentrate from wheat. NAXUS has been evaluated in a number of clinical studies for its effects on glycaemic control and benefits from a specific EFSA approved health claim for glycaemic control. NAXUS has also shown profound effects on the human microbiota with knock-on effects on the improvement of several metabolic processes.
Recent pre-clinical results obtained by Ghent University and Universite Catholique de Louvain (UCL) have been accepted in 2 peer reviewed journals. The paper published by Ghent University in the Journal of Agricultural and Food Chemistry, further confirms the highly selective effects of NAXUS on the gut microbiota based on a set of gut model studies. The manuscript published by UCL in British Journal of Nutrition, describes a novel downstream metabolic pathway which further helps to explain the positive effects of NAXUS on metabolic control, in a well-established animal model for obesity.
To further strengthen its NAXUS research program, BioActor has signed a Collaboration Agreement with Ghent University to study the effects of NAXUS on the gut microbiota and the downstream effects on gut barrier function. BioActor has already obtained strong pre-clinical data indicating that NAXUS affects markers for barrier function. BioActor is currently conducting a large clinical study to validate these effects in human volunteers. In this context, BioActor will provide Ghent University with gut biopsies, intestinal and fecal samples from this clinical trial to characterize the microbiota and correlate changes with downstream effects on gut barrier function.
About BioActor BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bioactives that address the metabolic syndrome and ageing related chronic health conditions. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
For more information, see www.bioactor.com or contact Hans van der Saag, Managing Director, on + 31 43 711 45 55, mail to: hans.vandersaag@bioactor.com